OBJECTIVE: This prospective study compared the diagnostic accuracy of imaging using an intact murine antigranulocyte antibody 99m Tcbesilesomab, and a murine antibody Fab′ fragment 99m Tc-sulesomab, in patients with suspected septically loosened total knee arthroplasty. METHODS: Images from 20 patients who underwent threephase bone scintigraphy followed by imaging using 99m Tc-besilesomab (n = 10) or 99m Tc-sulesomab (n = 10) were evaluated and compared. Final diagnosis was determined by microbiological evaluation of aspirated synovial fluid, intraoperative samples through the clinical course, or by long-term follow-up. RESULTS: Prosthesis infection was shown in 18 patients. At 4 and 24 h after intravenous injection, absolute uptake of 99m Tc-besilesomab was significantly higher than 99m Tc-sulesomab in infected knee joints. Infected-to-healthy knee activity ratios were similar at 4 and 24 h for 99m Tc-besilesomab and 99m Tcsulesomab. CONCLUSIONS: Both 99m Tcbesilesomab and 99m Tc-sulesomab had similar diagnostic accuracy for the detection of septic arthroplasty. If repeated use of immunoscintigraphy is needed for follow-up, 99m Tc-sulesomab should be preferred over 99m Tcbesilesomab since it is known to be well tolerated and without side effects or incompatibility reactions. KEY WORDS: TOTAL KNEE ARTHROPLASTY; RADIONUCLIDE IMAGING; 99M TC-ANTIGRANULOCYTE ANTIBODIES; BESILESOMAB; 99M TC-FAB′ FRAGMENTS; SULESOMAB; INFECTION •
Introduction
The increasing numbers of total joint arthroplasty procedures performed and the need to diagnose complications, such as loosening and infection, that can occur after the implantation of prosthetic components have prompted the use of new noninvasive diagnostic methods. 1, 2 Antigranulocyte scintigraphy, using monoclonal antibodies or antibody Fab′ fragments, is a promising diagnostic tool that is increasingly being used to detect prosthesis infection after total knee arthroplasty (TKA). 1, 2 This approach exploits the diapedesis and chemotaxis of leucocytes by directly targeting leucocyte antigens or receptors in vivo via S Gratz, P Reize, A Pfestroff et al. Imaging infection in septically loosened total knee arthroplasty administration of radiolabelled antigranulocyte monoclonal antibodies. 3 Several studies have evaluated the efficacy of antigranulocyte scintigraphy with 99m Tc-labelled monoclonal antibodies or Fab′ fragments for diagnosing infection in different clinical settings, including prosthesis infection after arthroplasty. 1, 2, 4 The agents most commonly used for imaging prosthesis infection have been immunoglobulin G (IgG) antibody directed against normal cross-reactive antigen-95 ( 99m Tc-besilesomab) 2 and the Fab′ fragment of IgG antibody directed against the glycoprotein cross-reactive antigen-90 ( 99m Tcsulesomab). 4 In particular, 99m Tc-sulesomab has been increasingly used for the diagnosis of infection after arthroplasty, with a variety of reported outcomes. 5 -7 A disadvantage of using intact murine monoclonal antibodies is the occurrence of allergic reactions in patients due to repeated antibody exposure and to the development of human antimouse antibodies (HAMA). 8, 9 A multicentre study, assessing the image quality of 99m Tc-besilesomab in peripheral osteomyelitis, detected HAMA in 16 of 116 (13.8%) patients. Antibody fragments, such as 99m Tc-sulesomab, rather than intact antibodies are being used as an option to avoid the HAMA response. Research has shown that 99m Tc-sulesomab is well tolerated and not associated with any patient sideeffects or the development of HAMA; 10 Fab′ fragment of IgG antibody lacks the Fcterminal responsible for the immune reactions.
Several studies have been performed in patients with septically loosened arthroplasty using intact 99m Tc-monoclonal antibodies 2, 7 or 99m Tc-Fab′ fragments. 4 The present study aimed to carry out direct comparison of the accuracy of imaging with 99m Tc-besilesomab versus 99m Tc-sulesomab for diagnosing knee prosthesis infection in patients with septically loosened arthroplasty.
Patients and methods

STUDY POPULATION
Data from patients with suspected septically loosened TKA, who underwent three-phase bone scintigraphy followed by imaging using 99m Tc-besilesomab or 99m Tc-sulesomab at the Department of Nuclear Medicine, Philipps University, Marburg, Germany, between June 2009 and November 2011, were prospectively reviewed. Patients were selected either for 99m Tc-besilesomab or 99m Tcsulesomab scintigraphy at the discretion of the surgeon and nuclear medicine physician. Surgery for TKA was performed in a variety of different orthopaedic departments at Philipps University. A detailed clinical examination was performed, blood samples were taken for routine haematological and biochemical analysis, and normal X-rays of the suspected area of prosthesis infection were obtained before carrying out scintigraphic imaging.
The study was approved by the Ethics Committee of the Department of Trauma, Reconstructive and Orthopaedic Surgery, Centre Bad Cannstatt, Stuttgart, Germany. All patients were fully informed about the study purpose and any potential risks, and gave their verbal informed consent prior to entry.
DIAGNOSTIC STANDARD
As previously already described 4 definitive diagnosis of prosthesis infection was established through culture of articular or intraoperative samples from patients undergoing revision surgery. A lesion was defined as infected when micro-organisms were found in cultures. Abscess formation and the presence of neutrophilic S Gratz, P Reize, A Pfestroff et al. Imaging infection in septically loosened total knee arthroplasty granulocytes were also considered as indicating infection. For patients with negative culture results and no clinical signs of infection, a minimum of 1 year's followup was required involving detailed clinical examinations and laboratory investigations, including erythrocyte sedimentation rate and C-reactive protein level and white blood cell count, to confirm the absence of prosthesis infection.
THREE-PHASE BONE SCINTIGRAPHY
Three-phase bone scintigraphy was performed with 740 MBq of 99m Tc-methylene diphosphonate (TECEOS ® ; CIS Bio, Berlin, Germany) injected intravenously (i.v.). Dynamic and planar images (in anterior and posterior views as per standard imaging protocol) were obtained with a large-field-ofview double-headed gamma camera (Prism 2000; Picker International, Cleveland, OH, USA), equipped with low-energy, highresolution, parallel-hole collimators. Energy discrimination was accomplished using a 20% window centred on the 140 keV 99m Tc peak. Dynamic acquisitions were performed using a 64 × 64 matrix at 5 s intervals for 60 s during arterial inflow (phase 1). Blood pool planar static images were obtained using a 256 × 256 matrix 5 min after injection and equilibration of the radionuclide (phase 2). Planar static imaging was performed 3 h after injection of the radionuclide (phase 3).
99M TC-BESILESOMAB AND 99M TC-SULESOMAB IMAGING
Antigranulocyte antibody imaging was performed with the murine 99m Tc-labelled IgG antibody 99m Tc-besilesomab (Scintimun ® ; CIS Bio International, Saclay, France) and with the murine 99m Tc-labelled Fab′ fragment 99m Tc-sulesomab (LeukoScan ® ; Immunomedics, Morris Plains, NJ, USA), which were supplied in lyophilized form in ready-to-use vials: the 99m Tc-besilesomab vials contained 1 mg of besilesomab; the 99m Tc-sulesomab vials contained 0.31 mg of sulesomab. Labelling was achieved by adding 1000 -1500 MBq of freshly eluted 99m Tc-pertechnetate in isotonic saline solution directly into the vials. The radioactivity dose for 99m Tc-besilesomab is normally 700 -900 MBq (19 -24 mCi) per injection (per patient) and for 99m Tcsulesomab it is normally 555 -925 MBq, as proposed by the respective guidelines of the European Association of Nuclear Medicine. 11 The quantity of protein to be given to each patient was, therefore, estimated as 0.65 -1.0 mg 99m Tc-besilesomab and 0.10 -0.31 mg 99m Tc-sulesomab.
Images were performed at least 48 h after bone imaging to avoid superimposition of the results. For 99m Tc-besilesomab and 99m Tcsulesomab examination, 555 -740 MBq 99m Tc-labelled antibodies per injection were slowly administered i.v. Planar and singlephoton emission computed tomography (SPECT) images were acquired 4 and 24 h after the injection. Planar images with a minimum of 500 000 counts/view (knee) were acquired in a 256 × 256 matrix using a large-field-of-view double-headed continuous, rotating gamma camera (Prism 2000) equipped with low-energy, high-resolution collimators, with 18 min acquisition time at 3600 counts/pixel, 60 s/stop and 30 s/frame. Transverse sections were reconstructed using a filtered back-projection algorithm (Butterworth filter cut-off frequency of 0.45 Nyquist and no attenuation compensation) with subsequent computation of coronal and sagittal slices.
VISUAL IMAGE ANALYSES
Visual image analyses of 99m Tc-besilesomab and 99m Tc-sulesomab scans were performed S Gratz, P Reize, A Pfestroff et al. Imaging infection in septically loosened total knee arthroplasty by two independent, nuclear medicine board-certified, experienced nuclear physicians (readers), each with > 5 years' experience with 99m Tc-besilesomab and 99m Tc-sulesomab scans, who were blinded to the results from other parts of the study and not involved in the evaluation of other assessments. The intensity of 99m Tcbesilesomab and 99m Tc-sulesomab uptake in each zone was graded on a four-point scale as follows: 1, uptake was similar to that in the bone marrow; 2, uptake was increased minimally over that in bone marrow; 3, uptake was distinctly higher than uptake in bone marrow; 4, uptake was two or more times greater than uptake in bone marrow.
QUANTITATIVE SCINTIGRAPHY
Absolute uptake evaluation
For quantitative analysis of absolute 99m Tcbesilesomab and 99m Tc-sulesomab uptake, regions of interest were drawn in the scintigrams around the suspected arthroplasty, in the healthy opposite knee joint and over the whole-body at 0, 4 and 24 h postinjection. Corrected uptake ratios for the infected arthroplasty-to-healthy opposite knee joint were calculated based on the corrected pixel count for each knee joint. Residual activity at the arthroplasty site was determined and calculated as a proportion of the injected dose (whole-body set at t = 0).
Relative uptake evaluation
Activity around the knee prosthesis was compared with activity of the pelvic bone marrow using regions of interest. Bone marrow regions of interest were drawn as large as possible, with the shape and size of the regions of interest around the knee being dependent on the shape and size of activity in this area. Regions of interest were compared from early-to late-phase views. Septic arthroplasty was present if the ratios in one of the regions of interest around the arthroplasty increased by > 10% from the early to the late phase; the 10% threshold allowed differentiation between septic and aseptic abnormalities of joint prostheses. 7 A scan was regarded as true-positive when an infectious or inflammatory cause for the abnormal uptake was confirmed by culture and laboratory findings. It was scored as false-positive when an infectious or inflammatory basis for the uptake was unconfirmed. A false-negative scan was defined as a scan without abnormal uptake around the arthroplasty, although infectious or inflammatory aetiology was subsequently established. A true-negative scan was defined as a normal scan obtained in a patient, with no infectious or inflammatory basis found during subsequent extensive investigations.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Sensitivity, specificity and diagnostic accuracy for 99m Tcbesilesomab and 99m Tc-sulesomab in the diagnosis of arthroplasty infection were calculated by comparing the results of the three-phase bone scintigraphy and the 99m Tcbesilesomab and 99m Tc-sulesomab imaging examinations with the definitive diagnostic standard (based on the culture results). These values for 99m Tc-besilesomab and 99m Tcsulesomab were calculated separately for each reader, and quantitative measurements were made according to standard algorithms. Interobserver agreement for each imaging modality was determined using κ-statistics: κ < 0.40 indicated poor agreement; 0.40 -0.75 indicated fair to good agreement; and > 0.75 indicated excellent agreement. Diagnostic confidence was calculated separately for sensitivity and S Gratz, P Reize, A Pfestroff et al. Imaging infection in septically loosened total knee arthroplasty specificity values and was compared with the sign test. The nonparametric Mann-Whitney U test was used to analyse variables across the patients studied. A value of P < 0.05 was considered to be statistically significant.
Results
DEMOGRAPHIC AND INFECTION DATA
A total of 20 patients with suspected arthroplasty infection were included in the study. All underwent three-phase bone scintigraphy followed by imaging using either 99m Tc-besilesomab (n = 10) or 99m Tcsulesomab (n = 10). The median time from the arthroplasty for the patients was 31 months (range 2 -148 months) at the time of investigation. Six patients had undergone a unicompartmental replacement (partial knee resurfacing implant or total knee implant) and 14 patients had undergone cemented arthroplasty, including femoral head, tibial plate and meniscus replacement plate. Two of the patients with cemented arthroplasty had undergone patellar plate replacement. There were six cases of revision unicompartmental replacements, five cases of revision arthroplasty and nine cases of primary arthroplasty. Mean ± SD patient age at the time of imaging with 99m Tcbesilesomab and 99m Tc-sulesomab was 67.9 ± 8.3 years.
Of the 20 patients examined, 18 were confirmed with infection on the basis of microbiological tests; joint aspiration and laboratory findings excluded infection in two patients.
THREE-PHASE BONE SCINTIGRAPHY
Three-phase bone scintigraphy showed 15 true-positives, two false-positives and three false-negatives for infection on the bases of microbiological, laboratory and clinical findings. Overall sensitivity, specificity and diagnostic accuracy were 100%, 90% and 75%, respectively.
99M
TC-BESILESOMAB AND 99M
TC-SULESOMAB IMAGING
Visual image analysis and interobserver agreement
Using an increased 99m Tc-besilesomab and 99m Tc-sulesomab uptake of grades 3 and 4, the imaging results with 99m Tc-besilesomab and 99m Tc-sulesomab were true-positive in 15 and 14 patients, respectively, for both readers. Imaging with 99m Tc-sulesomab was false-positive in one patient (reader 1) and two patients (reader 2). For two of these patients, analysis of articular or intraoperative samples revealed inflammatory cells -including histiocytes, giant cells and fibrovascular tissueassociated with foreign body reactions. Falsenegative results were not found by either reader for imaging with 99m Tc-besilesomab or 99m Tc-sulesomab. Imaging with 99m Tc-besilesomab and 99m Tc-sulesomab both gave sensitivity, specificity and accuracy results for both readers 1 and 2 of 100%, 94% and 95%, respectively, with excellent interobserver agreement in most patients. Interobserver agreement was reduced in one patient with strong reactive aseptical inflammation due to severe arthroplasty loosening, because nonspecific uptake of 99m Tc-sulesomab was slighter greater than for 99m Tc-besilesomab.
Quantitative scintigraphy
Absolute uptake evaluation. Absolute uptake in regions around the infected arthroplasty as a fraction of whole body activity was significantly higher (P < 0.05) for 99m Tc-besilesomab (6.1%) compared with 99m Tc-sulesomab (3.5%). No significant difference was observed in the absolute uptake of 99m Tc-besilesomab at 4 and 24 h S Gratz, P Reize, A Pfestroff et al. Imaging infection in septically loosened total knee arthroplasty after i.v. injection (ranging from 3.2% to 5.1% of the injected dose). Lower absolute uptake values were found for 99m Tcsulesomab at 4 and 24 h after injection (ranging from 1.8% to 2.9% of the injected dose). Uptake of 99m Tc-besilesomab in the infected regions around the arthroplasty at 4 and 24 h after injection was 1.4 -1.8-fold higher than for 99m Tc-sulesomab uptake. Infected-to-healthy knee activity ratios were similar at 4 and 24 h for 99m Tc-besilesomab (mean ± SD 2.1 ± 0.3 versus 1.9 ± 0.2) and 99m Tc-sulesomab (mean ± SD 1.9 ± 0.2 versus 1.7 ± 0.3).
Relative uptake evaluation. Quantitative evaluations of 99m Tc-besilesomab and 99m Tcsulesomab in patients with septic loosened arthroplasty gave true-positive results in all 18 patients; images from two male patients at 4 h postinjection are shown in Fig. 1 . The ratio of activity around the knee prosthesis, compared with activity of the pelvic bone marrow, in one of the regions of interest around the arthroplasty increased between 51% and 161% for 99m Tc-besilesomab and between 55% and 145% for 99m Tc-sulesomab from the early to the late phase. No evaluations of 99m Tc-besilesomab and 99m Tcsulesomab gave false-positive or falsenegative results in patients with septic loosened arthroplasty.
Discussion
Different nuclear medicine bone imaging modalities are currently used to show alterations in the bone caused by bone destruction, bone infection, bone fracture, vascular ischaemia or other reasons. 12 Although 99m Tc-methylene diphosphonate is highly sensitive in detecting any kind of pathological bone turnover, its specificity is limited. 13 With 99m Tc-methylene diphosphonate, the ability to differentiate between tumours, activated osteoarthritis and noninfectious inflammatory lesions is often not possible. 13 Thus, the use of immunoscintigraphy in combination with 99m Tc-methylene diphosphonate can increase both sensitivity and specificity when B Imaging infection in septically loosened total knee arthroplasty using agents that target neutrophils that have infiltrated the bone marrow. The use of radiolabelled autologous leucocytes for the imaging of bone infection is well accepted, 14 whereas using radiolabelled antibodies directed against epitopes present on granulocytes requires further evaluation. 15 The present study achieved excellent results with the intact antigranulocyte antibody 99m Tc-besilesomab and the Fab′ fragment 99m Tc-sulesomab in patients with arthroplasty infections. Interobserver agreement and diagnostic accuracy in patients with arthroplasty infections were comparable for both imaging modalities. The diagnostic efficacy results were consistent with previous studies in similar patient populations using either 99m Tcbesilesomab or 99m Tc-sulesomab. 2, 4, 7 Absolute quantitative evaluation demonstrated a significantly higher uptake in infected arthroplasty regions for 99m Tcbesilesomab compared with 99m Tc-sulesomab at 4 and 24 h. There are two possible explanations for these observed differences. First, labelled antigranulocyte antibodies can accumulate in infected areas and in healthy bone marrow; 2,15 -17 thus, scintigraphic differentiation between chronic or, more often, nonspecific inflammation can be difficult when using labelled antigranulocyte antibodies. 2 Secondly, the different sizes and protein weights of 99m Tc-besilesomab and 99m Tc-sulesomab may contribute to their uptake. The 99m Tc-besilesomab and 99m Tcsulesomab were supplied in vials and had to be reconstituted according to procedures proposed by the respective guidelines of the European Association of Nuclear Medicine. 11 The quantity of protein given to each patient was, therefore, estimated to be 0.65 -1.0 mg 99m Tc-besilesomab and 0.10 -0.31 mg 99m Tcsulesomab, with 99m Tc-besilesomab containing a much greater protein content. Despite the smaller molecular size of the Fab′ fragments (50 kDa) 2 compared with intact antibodies (180 kDa), 2 the specific binding affinity (K a ) for 99m Tc-sulesomab is strong (K a = 0.5 × 10 8 ± 0.2 × 10 8 l/mol) 18 and comparable to that of 99m Tc-besilesomab (K a = 2.0 × 10 9 ± 0.1 l/mol). This is consistent with results of the relative quantitative evaluation of uptake shown in the present study, which demonstrated a similar diagnostic accuracy for 99m Tc-besilesomab and 99m Tc-sulesomab when comparing activity around the knee prosthesis with activity of the pelvic bone marrow within 24 h. Limitations of the present study included a high prevalence of infection, which was related to the prospective nature of the study; thus, there was a high level of confidence for the sensitivities of both agents. Another limitation was the small number of patients analysed.
Since extended statistical evaluations have been performed previously, 2, 4, 6, 7 the present study focused instead on the imaging quality of 99m Tcbesilesomab and 99m Tc-sulesomab.
In conclusion, the present study showed that 99m Tc-besilesomab and 99m Tc-sulesomab achieved similar diagnostic accuracy for detection of septic arthroplasty. It has been shown that 99m Tc-sulesomab is well tolerated and has few side effects or incompatibility reactions; 10 thus, if repeated use of immunoscintigraphy is needed for follow-up, 99m Tc-sulesomab may be preferred.
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